RETRACTED: Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus (Retracted Article)

被引:198
作者
Hemmingsen, Bianca [1 ]
Lund, Soren S. [2 ]
Gluud, Christian [1 ]
Vaag, Allan [3 ]
Almdal, Thomas [2 ]
Hemmingsen, Christina
Wetterslev, Jorn
机构
[1] Univ Copenhagen Hosp, Rigshosp, Ctr Clin Intervent Res, Dept 3344,Copenhagen Trial Unit,Cochrane Hepatobi, DK-2100 Copenhagen, Denmark
[2] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[3] Rigshosp, Copenhagen N, Denmark
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2011年 / 06期
关键词
TRIAL SEQUENTIAL-ANALYSIS; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE CONTROL; FASTING GLUCOSE-LEVELS; ACUTE CORONARY EVENTS; 10-YEAR FOLLOW-UP; MULTIFACTORIAL INTERVENTION; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; INSULIN-TREATMENT;
D O I
10.1002/14651858.CD008143.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Patients with type 2 diabetes mellitus (T2D) exhibit an increased risk of cardiovascular disease and mortality compared to the background population. Observational studies report a relationship between reduced blood glucose and reduced risk of both micro-and macrovascular complications in patients with T2D. Objectives To assess the effects of targeting intensive versus conventional glycaemic control in T2D patients. Search strategy Trials were obtained from searches of CENTRAL (The Cochrane Library), MEDLINE, EMBASE, Science Citation Index Expanded, LILACS, and CINAHL (until December 2010). Selection criteria We included randomised clinical trials that prespecified different targets of glycaemic control in adults with T2D. Data collection and analysis Two authors independently assessed the risk of bias and extracted data. Dichotomous outcomes were assessed by risk ratios (RR) and 95% confidence intervals (CI). Main results Twenty trials randomised 16,106T2D participants to intensive control and 13,880 T2D participants to conventional glycaemic control. The mean age of the participants was 62.1 years. The duration of the intervention ranged from three days to 12.5 years. The number of participants in the included trials ranged from 20 to 11,140. There was no significant difference between targeting intensive andconventional glycaemic control for all-cause mortality (RR 1.01, 95% CI 0.90 to 1.13; 29,731 participants, 18 trials) or cardiovascular mortality (RR 1.06, 95% CI 0.90 to 1.26; 29,731 participants, 18 trials). Trial sequential analysis (TSA) showed that a 10% RR reduction could be refuted for all-cause mortality. Targeting intensive glycaemic control did not show a significant effect on the risk of non-fatal myocardial infarction in the random-effects model but decreased the risk in the fixed-effect model (RR 0.86, 95% CI 0.78 to 0.96; P = 0.006; 29,174 participants, 12 trials). Targeting intensive glycaemic control reduced the risk of amputation (RR 0.64, 95% CI 0.43 to 0.95; P = 0.03; 6960 participants, 8 trials), the composite risk of microvascular disease (RR 0.89, 95% CI 0.83 to 0.95; P = 0.0006; 25,760 participants, 4 trials), retinopathy (RR 0.79, 95% CI 0.68 to 0.92; P = 0.002; 10,986 participants, 8 trials), retinal photocoagulation (RR 0.77, 95% CI 0.61 to 0.97; P = 0.03; 11,142 participants, 7 trials), and nephropathy (RR 0.78, 95% CI 0.61 to 0.99; P = 0.04; 27,929 participants, 9 trials). The risks of both mild and severe hypoglycaemia were increased with targeting intensive glycaemic control but substantial heterogeneity was present. The definition of severe hypoglycaemia varied among the included trials; severe hypoglycaemia was reported in 12 trials that included 28,127 participants. TSA showed that firm evidence was reached for a 30% RR increase in severe hypoglycaemic when targeting intensive glycaemic control. Subgroup analysis of trials exclusively dealing with glycaemic control in usual care settings showed a significant effect in favour of targeting intensive glycaemic control for non-fatal myocardial infarction. However, TSA showed more trials are needed before firm evidence is established. Authors' conclusions The included trials did not show significant differences for all-cause mortality and cardiovascular mortality when targeting intensive glycaemic control compared with conventional glycaemic control. Targeting intensive glycaemic control reduced the risk of microvascular complications while increasing the risk of hypoglycaemia. Furthermore, intensive glycaemic control might reduce the risk of non-fatal myocardial infarction in trials exclusively dealing with glycaemic control in usual care settings.
引用
收藏
页数:236
相关论文
共 192 条
[1]   GLYCEMIC CONTROL AND COMPLICATIONS IN TYPE-II DIABETES - DESIGN OF A FEASIBILITY TRIAL [J].
ABRAIRA, C ;
EMANUELE, N ;
COLWELL, J ;
HENDERSON, W ;
COMSTOCK, J ;
LEVIN, S ;
NUTTALL, F ;
SAWIN, C .
DIABETES CARE, 1992, 15 (11) :1560-1571
[2]   VETERANS AFFAIRS COOPERATIVE STUDY ON GLYCEMIC CONTROL AND COMPLICATIONS IN TYPE-II DIABETES (VA CSDM) - RESULTS OF THE FEASIBILITY TRIAL [J].
ABRAIRA, C ;
COLWELL, JA ;
NUTTALL, FQ ;
SAWIN, CT ;
NAGEL, NJ ;
COMSTOCK, JP ;
EMANUELE, NV ;
LEVIN, SR ;
HENDERSON, W ;
LEE, HS .
DIABETES CARE, 1995, 18 (08) :1113-1123
[3]   Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes [J].
Abraira, C ;
Colwell, J ;
Nuttall, F ;
Sawin, CT ;
Henderson, W ;
Comstock, JP ;
Emanuele, NV ;
Levin, SR ;
Pacold, I ;
Lee, HS ;
Silbert, CK ;
Cxypoliski, R ;
Vasquez, M ;
Kernan, D ;
Niewoehner, C ;
Backes, M ;
Bradley, M ;
Bradley, M ;
Crow, R ;
Rubino, F ;
Bushnell, D ;
Pfeifer, M ;
Service, FJ ;
Howard, B ;
Chew, E ;
Hoogwerf, B ;
Seigel, D ;
Clark, CM ;
Olefsky, JM ;
Porte, D ;
Sussman, KE ;
Johnson, N ;
Christine, B ;
Tir, K ;
Sather, M ;
Day, P ;
Morgan, N ;
Deykin, D ;
Gold, J ;
Huang, P .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) :181-188
[4]   Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2 Veterans Affairs Diabetes Trial [J].
Abraira, C ;
Duckworth, W ;
McCarren, M ;
Emanuele, N ;
Arca, D ;
Reda, D ;
Henderson, W .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2003, 17 (06) :314-322
[5]   Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report [J].
Abraira, C. ;
Duckworth, W. C. ;
Moritz, T. .
DIABETES OBESITY & METABOLISM, 2009, 11 (02) :150-156
[6]   Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes: VA feasibility study on glycemic control and complications (VA CSDM) [J].
Abraira, C ;
Henderson, WG ;
Colwell, JA ;
Nuttall, FQ ;
Comstock, JP ;
Emanuele, NV ;
Levin, SR ;
Sawin, CT ;
Silbert, CK .
DIABETES CARE, 1998, 21 (04) :574-579
[7]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[8]  
2-S
[9]   The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death - A population-based study of 13000 men and women with 20 years of follow-up [J].
Almdal, T ;
Scharling, H ;
Jensen, JS ;
Vestergaard, H .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (13) :1422-1426
[10]   Standards of medical care in diabetes 2008 [J].
不详 .
DIABETES CARE, 2008, 31 :S12-S54